Detailed information for compound 1972356

Basic information

Technical information
  • TDR Targets ID: 1972356
  • Name: N-[7-[(2R)-2-acetamidopropoxy]-4-[(4-bromo-2- fluorophenyl)amino]quinazolin-6-yl]prop-2-ena mide
  • MW: 502.336 | Formula: C22H21BrFN5O3
  • H donors: 3 H acceptors: 4 LogP: 3.69 Rotable bonds: 10
    Rule of 5 violations (Lipinski): 2
  • SMILES: C=CC(=O)Nc1cc2c(ncnc2cc1OC[C@H](NC(=O)C)C)Nc1ccc(cc1F)Br
  • InChi: 1S/C22H21BrFN5O3/c1-4-21(31)28-19-8-15-18(9-20(19)32-10-12(2)27-13(3)30)25-11-26-22(15)29-17-6-5-14(23)7-16(17)24/h4-9,11-12H,1,10H2,2-3H3,(H,27,30)(H,28,31)(H,25,26,29)/t12-/m1/s1
  • InChiKey: AXWQPHKBZRUJSS-GFCCVEGCSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • N-[7-[(2R)-2-acetamidopropoxy]-4-[(4-bromo-2-fluoro-phenyl)amino]quinazolin-6-yl]prop-2-enamide
  • N-[7-[(2R)-2-acetamidopropoxy]-4-[(4-bromo-2-fluorophenyl)amino]-6-quinazolinyl]prop-2-enamide
  • N-[7-[(2R)-2-acetamidopropoxy]-4-[(4-bromo-2-fluoro-phenyl)amino]quinazolin-6-yl]acrylamide

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens kinase insert domain receptor Starlite/ChEMBL No references
Homo sapiens epidermal growth factor receptor Starlite/ChEMBL No references

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Schistosoma japonicum IPR006212,Furin-like repeat;IPR009030,Growth factor, receptor,domain-containing Get druggable targets OG5_128597 All targets in OG5_128597
Echinococcus granulosus melanoma receptor tyrosine protein kinase Get druggable targets OG5_128597 All targets in OG5_128597
Schistosoma mansoni tyrosine kinase Get druggable targets OG5_128597 All targets in OG5_128597
Onchocerca volvulus Get druggable targets OG5_130320 All targets in OG5_130320
Brugia malayi Furin-like cysteine rich region family protein Get druggable targets OG5_128597 All targets in OG5_128597
Echinococcus multilocularis epidermal growth factor receptor Get druggable targets OG5_128597 All targets in OG5_128597
Schistosoma japonicum Receptor tyrosine-protein kinase erbB-2 precursor, putative Get druggable targets OG5_128597 All targets in OG5_128597
Onchocerca volvulus Tyrosine kinase homolog Get druggable targets OG5_130320 All targets in OG5_130320
Schistosoma mansoni tyrosine kinase Get druggable targets OG5_128597 All targets in OG5_128597
Schistosoma japonicum Epidermal growth factor receptor precursor, putative Get druggable targets OG5_128597 All targets in OG5_128597
Brugia malayi Immunoglobulin I-set domain containing protein Get druggable targets OG5_130320 All targets in OG5_130320
Echinococcus granulosus epidermal growth factor receptor Get druggable targets OG5_128597 All targets in OG5_128597
Schistosoma japonicum IPR000494,EGF receptor, L domain,domain-containing Get druggable targets OG5_128597 All targets in OG5_128597
Loa Loa (eye worm) TK/KIN16 protein kinase Get druggable targets OG5_130320 All targets in OG5_130320
Schistosoma mansoni tyrosine kinase Get druggable targets OG5_128597 All targets in OG5_128597
Schistosoma japonicum Receptor tyrosine-protein kinase erbB-4 precursor, putative Get druggable targets OG5_128597 All targets in OG5_128597
Schistosoma japonicum Epidermal growth factor receptor precursor, putative Get druggable targets OG5_128597 All targets in OG5_128597
Loa Loa (eye worm) TK/EGFR protein kinase Get druggable targets OG5_128597 All targets in OG5_128597
Schistosoma japonicum Epidermal growth factor receptor precursor, putative Get druggable targets OG5_128597 All targets in OG5_128597
Schistosoma mansoni tyrosine kinase Get druggable targets OG5_128597 All targets in OG5_128597
Echinococcus multilocularis epidermal growth factor receptor Get druggable targets OG5_128597 All targets in OG5_128597
Schistosoma japonicum expressed protein Get druggable targets OG5_128597 All targets in OG5_128597
Schistosoma japonicum hypothetical protein Get druggable targets OG5_128597 All targets in OG5_128597
Schistosoma japonicum ko:K05085 receptor tyrosine-protein kinase erbB-4, putative Get druggable targets OG5_128597 All targets in OG5_128597
Schistosoma mansoni tyrosine kinase Get druggable targets OG5_128597 All targets in OG5_128597
Schistosoma japonicum Epidermal growth factor receptor precursor, putative Get druggable targets OG5_128597 All targets in OG5_128597
Schistosoma japonicum Epidermal growth factor receptor precursor, putative Get druggable targets OG5_128597 All targets in OG5_128597
Schistosoma japonicum Tyrosine-protein kinase transforming protein erbB, putative Get druggable targets OG5_128597 All targets in OG5_128597
Echinococcus granulosus epidermal growth factor receptor Get druggable targets OG5_128597 All targets in OG5_128597
Schistosoma mansoni tyrosine kinase Get druggable targets OG5_128597 All targets in OG5_128597
Echinococcus multilocularis Get druggable targets OG5_128597 All targets in OG5_128597
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Loa Loa (eye worm) TK/KIN16 protein kinase 0.0184 0.2341 1
Loa Loa (eye worm) TK/INSR protein kinase 0.0059 0.0606 0.2589
Onchocerca volvulus Tyrosine kinase homolog 0.0172 0.2174 1
Echinococcus multilocularis 0.0056 0.0567 0.2325
Echinococcus granulosus insulin receptor 0.0059 0.0606 0.2627
Loa Loa (eye worm) hypothetical protein 0.0018 0.004 0.017
Brugia malayi Immunoglobulin I-set domain containing protein 0.0184 0.2341 1
Mycobacterium tuberculosis Conserved hypothetical protein 0.0736 1 0.5
Loa Loa (eye worm) TK/EGFR protein kinase 0.0181 0.2306 0.9853
Loa Loa (eye worm) hypothetical protein 0.0018 0.004 0.017
Echinococcus granulosus melanoma receptor tyrosine protein kinase 0.0098 0.115 0.4987
Echinococcus granulosus epidermal growth factor receptor 0.0098 0.115 0.4987
Schistosoma mansoni tyrosine kinase 0.0096 0.1122 0.4864
Schistosoma mansoni tyrosine kinase 0.0096 0.1122 0.4864
Echinococcus multilocularis insulin growth factor 1 receptor beta 0.0059 0.0606 0.2498
Schistosoma mansoni tyrosine kinase 0.0098 0.115 0.4987
Mycobacterium leprae conserved hypothetical protein 0.0736 1 0.5
Echinococcus multilocularis epidermal growth factor receptor 0.0098 0.115 0.4899
Echinococcus granulosus insulin growth factor 1 receptor beta 0.0059 0.0606 0.2627
Brugia malayi Furin-like cysteine rich region family protein 0.0181 0.2306 0.9801
Echinococcus granulosus roundabout 2 0.0018 0.004 0.0173
Mycobacterium tuberculosis Conserved protein 0.0736 1 0.5
Schistosoma mansoni tyrosine kinase 0.0181 0.2306 1
Mycobacterium ulcerans hypothetical protein 0.0736 1 0.5
Echinococcus granulosus epidermal growth factor receptor 0.0181 0.2306 1
Schistosoma mansoni tyrosine kinase 0.0096 0.1122 0.4864
Schistosoma mansoni tyrosine kinase 0.0059 0.0606 0.2627
Schistosoma mansoni tyrosine kinase 0.0059 0.0606 0.2627
Echinococcus multilocularis insulin receptor 0.0059 0.0606 0.2498
Mycobacterium ulcerans hypothetical protein 0.0736 1 0.5
Echinococcus multilocularis epidermal growth factor receptor 0.0181 0.2306 1
Schistosoma mansoni tyrosine kinase 0.0098 0.115 0.4987

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 29 nM BindingDB_Patents: Tyrosine Kinase Assay. EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM. ChEMBL. No reference
IC50 (binding) = 29 nM BindingDB_Patents: Tyrosine Kinase Assay. EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM. ChEMBL. No reference
IC50 (binding) = 158 nM BindingDB_Patents: Tyrosine Kinase Assay. VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM. ChEMBL. No reference
IC50 (binding) = 158 nM BindingDB_Patents: Tyrosine Kinase Assay. VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM. ChEMBL. No reference

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

No literature references available for this target.

If you have references for this compound, please enter them in a user comment (below) or Contact us.